Pain Management

These populations are also more likely to receive opioid analgesic therapies.

The CDC first released opioid prescribing guidelines in 2016.

A poster from ASHP Midyear 2023 demonstrated the effectiveness of liposomal bupivacaine as it is used for cesarean section procedures, regarded as an area with increasing utilization.

Three poster presented at the ASHP Midyear Clinical Meeting delved deeper into perioperative pain management.

Despite societal need, stigma around MAT and MOUD still exists.

Despite a wealth of data proving their efficacy for acute and chronic pain, these products remain underutilized in the United States.

Although there were some differences in response after dosing, both OTC and oral prescriptions demonstrated statistically significant improvements in pain.

Filling a prescription for a controlled substance requires more oversight than the average prescription.

Zavegepant joins other CGRP antagonists as an option for individuals experiencing migraine.

The alert was implemented after passage of a state senate bill.

Study results add to the body of evidence demonstrating the efficacy of CGRP inhibitors for migraine treatment and prophylaxis.

This treatment is the first and only long-acting buprenorphine injectable with weekly and monthly doses.

A new meta-analysis found duloxetine to be the only commonly prescribed medication that was effective.

Only the 60 mg dose of atogepant is approved for chronic migraine prevention.

A new study from JAPHA explores the link between OUD and social factors.

Naloxone hydrochloride nasal spray (Narcan) 4 mg is expected to be available over the counter in late summer 2023.

Vitamin D supplementation may be an effective and safe adjunctive prophylactic therapy to topiramate for children who experience migraine attacks, showed a study conducted in Saudi Arabia.

The test is intended to complement the company’s TBI plasma test, which received FDA clearance in 2021.

Nerivio received clearance in January 2021 for use in acute migraine.

The letter outlined 7 steps that the Biden administration can take without the need for additional legislation.

The number of digital therapeutics available for migraine is likely to expand.

Long, hot showers and cold, dry air can contribute to psoriasis flare-ups during the winter months.

New legislation removes what many perceived as a barrier to treating opioid use disorder.